An expert discusses the case of a patient with metastatic castration-resistant prostate cancer (CRPC) who progressed after ...

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate ...

The understanding of the biology of CRPC and the evidence that CRPC still remains driven by androgen receptor signaling led to the discovery of new therapeutic targets. In the last few years ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Triple-negative breast cancer is a subgroup of breast cancer with scarce targeted treatment options, resulting in a poor ...

Key contributors to PrCa progression include genetic mutations, elevated androgen receptor expression ... advance to castration-resistant PrCa (CRPC), presenting a significant therapeutic hurdle.

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

Brain metastases from prostate cancer (PC) seem to be more frequent than in the past, possibly because advances in the treatment of patients with castration-resistant PC have prolonged their survival.

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing outcomes for 177 Lu-PSMA-617 with and without concurrent use of androgen receptor pathway ...

androgen receptor inhibitor (ARi) plus ADT or a combination of the chemotherapy docetaxel and ADT. Despite this treatment, most men with mHSPC will eventually progress to castration-resistant prostate ...